Physicians, compounding pharmacies, telehealth clinics, and specialty peptide providers deserve better than automated rejections. eData is your personal payment concierge: we review your profile, identify the right processors from our private network, and handle the entire matching process on your behalf. Card, ACH, Crypto, Zelle and more.
Request Concierge Matching →It is not just Stripe. Every mainstream processor uses the same automated risk algorithms. Physicians, 503A pharmacies, and telehealth clinics all trigger them. Here is who is doing it and why.
Get Matched Now →Auto-detects peptide keywords and terminates accounts within 2 to 6 weeks of first transaction. Funds held 90 to 180 days. Physicians and pharmacies receive no warning and no appeal pathway.
MCC mis-classificationBans entire categories of pharma and research chemical merchants at the account level. Appeals rarely succeed. Rolling reserves held 180 days post-termination even for fully licensed providers.
Category prohibitionRisk engine flags pharmaceutical terminology instantly. Compounding pharmacies and GLP-1 clinics are terminated without notice, often mid-month during active patient billing cycles.
Algorithm terminationPowered by Stripe and inheriting the same prohibited product list. Even fully compliant LegitScript-certified stores have been shut down after a manual review of product descriptions.
Prohibited product listPayPal's gateway shares the same prohibited products policy. Telehealth providers and physicians billing for peptide therapy subscriptions are particularly vulnerable to sudden termination.
PayPal policy inheritanceStripe-backed and inheriting identical restrictions. Physicians who migrate from Shopify to WooCommerce encounter the same outcome. The underlying banking relationship is the same.
Stripe-backed risk policyIncreased scrutiny on health and pharmaceutical merchants after 2024 Mastercard BRAM policy updates. Med spas and clinics are frequently de-platformed without warning.
Mastercard BRAM pressureHas terminated compounding pharmacy and research peptide accounts during periodic portfolio reviews triggered by their acquiring bank partners.
Portfolio risk reviewProhibits research chemicals and non-FDA-approved therapeutic products. Merchants selling BPC-157, TB-500, semaglutide analogs, or related compounds are declined or later terminated.
Prohibited categoryThe solution is not reapplying to mainstream platforms. It is accessing specialized high-risk acquirers who specifically underwrite your category.
Request Your Concierge Matching →Doctors, pharmacists, and specialty clinic operators need payment processing now, not in 6 weeks. Our concierge network is built for your timeline and your compliance model.
| Client Type | Priority | What They Need |
|---|---|---|
| Physicians and Telehealth Providers | Priority | Recurring billing, virtual terminal, MCC 8099, HSA/FSA acceptance, multi-state compliance |
| Compounding Pharmacies (503A and 503B) | Priority | Subscription billing, LegitScript-aligned acquirers, ACH, HSA/FSA, prescription workflow support |
| Specialty and Functional Medicine Clinics | Priority | Hybrid card plus ACH, monthly wellness program billing, virtual terminal, chargeback tools |
| Med Spas and Anti-Aging Clinics | In-person EMV plus card-not-present, chargeback protection, peptide therapy subscriptions | |
| GLP-1 and Semaglutide Providers | Compliant framing, subscription billing, domestic US accounts, low fees, virtual terminal | |
| Research Peptide Vendors (RUO) | Card plus ACH plus crypto rails, research-only compliance, no LegitScript required for many | |
| Pharmaceutical Distributors | International and offshore rails, high volume, multi-currency, global acquiring partners | |
| Nutraceutical and Supplement Brands | Multi-gateway stack, backup processing, recurring billing, Shopify and WooCommerce integration |
Compound names listed for merchant identification purposes only. eData does not manufacture, sell, or distribute any pharmaceutical or research products.
We handle the complexity of pharmaceutical merchant placement so you can focus on patient care. No applications sent cold. No wasted time on certain rejections.
Complete our short intake form in under 2 minutes. Business type, volume, current situation, and preferred payment rails. No bank statements required at this stage.
Under 2 minutesA pharmaceutical payment specialist reviews your profile personally. We assess your compliance model, volume, location, and LegitScript status to identify the right processor fit.
Within 4 hoursWe present 1 to 3 vetted processors specifically suited to your profile. You apply only where you will be approved. No shotgun applications. No hard pulls at the wrong banks.
Within 24 hoursOnce approved, we support gateway integration, documentation, and account setup until you are live and processing. Ongoing support available for account health monitoring.
1 to 3 weeks totalHaving these documents ready significantly accelerates approval timelines. Our team confirms the exact list for your specific processor match when you apply.
Approval and onboarding typically takes 1 to 3 weeks depending on your program and documentation completeness.
Begin Your Application Now →Processors conduct live website reviews during underwriting. Non-compliant sites are the leading cause of rejection for otherwise qualified merchants.
"For Research Use Only, Not for Human Consumption" must appear clearly on every product page, homepage, and checkout flow for research-model accounts.
No statements implying medical benefit, weight loss, or treatment outcomes. Unapproved claims are the single most common reason for post-approval account termination.
COAs from FDA-registered laboratories must be accessible on your site or available upon request. Processors verify quality documentation during underwriting.
Transparent subscription terms, cancellation policy, and refund procedures reduce chargebacks and are required by Visa and Mastercard for recurring billing accounts.
Telehealth providers and compounding pharmacies must clearly display provider credentials, prescription workflow, and licensed oversight. LegitScript certification strongly preferred.
Using Ozempic, Wegovy, or Mounjaro alongside compounded or research products is flagged by Mastercard's 2026 BRAM update and triggers account review.
Complete policies for shipping timelines, customer support contact, and data privacy are required by all card-not-present processors for pharmaceutical merchants.
SSL certificate required on all pages. PCI-compliant checkout flow. Processors will not onboard sites with security warnings or unencrypted payment forms.
Not sure if your site is compliant? Submit your application and our team will review it as part of the concierge process.
Get a Free Compliance Review →Diversification across multiple payment rails is the foundation of processing stability for medical and pharmaceutical merchants.
The primary rail for online and in-clinic payments. Mainstream processors terminate pharmaceutical merchants on algorithmic detection. We connect you with acquirers who specifically underwrite your category with compliant card-not-present programs.
Lower chargeback exposure, fees of 0.5 to 2%, and no card brand restrictions. Essential for high average order values, recurring peptide therapy subscriptions, and compounding pharmacy programs with monthly patient billing.
Patients pay with Visa or Apple Pay as usual. You receive USDC or USDT directly to your wallet. No MCC classification applied. No rolling reserve. No freeze risk. Fees of 1 to 3%. Setup in minutes for eligible merchants.
Widely used by telehealth patients for consultation billing. Fast, domestic, zero chargebacks. Best deployed alongside card and ACH rails as a fully diversified payment stack for medical practices.
SEPA for EU-based providers, UPI for India-focused operations, and offshore acquiring for high-volume international pharmaceutical distributors operating across multiple jurisdictions.
Accept payments over phone or during a patient consultation. Critical for physicians managing monthly peptide therapy programs including semaglutide, BPC-157, CJC-1295, and Ipamorelin with automatic subscription billing.
You have been misled by processors and rejected without explanation. Here is how we address every real obstacle physicians and clinics face.
"I have applied everywhere and been rejected every time."
"My patient billing funds were frozen after the shutdown."
"The fees were 7 to 8 percent and my practice could not absorb that."
"We were put on the MATCH list after a wrongful processor shutdown."
"We do not have LegitScript and brokers say it is mandatory."
"As a licensed physician, I assumed this process would be straightforward."
We match you to the right category based on your sales model, volume, LegitScript status, and compliance profile.
Patients pay by card as usual. You receive stablecoins directly to your wallet. No MCC code, no reserve, no freeze risk. No LegitScript required. Eligible merchants can be live in minutes.
Minutes to 60 secondsDomestic US acquiring banks that specifically underwrite research peptide and pharmaceutical RUO merchants. No LegitScript required for many RUO models. Card plus ACH supported.
Same day to 3 daysSpecialized high-risk acquirers for 503A compounding pharmacies, telehealth physicians, and GLP-1 clinical programs. Better long-term terms and lower reserves for certified merchants.
24 to 72 hoursInternational banking partners with higher volume tolerance for global pharmaceutical distributors and research vendors. Multi-currency, SEPA, and alternative payment bridges.
1 to 2 daysPlacement across multiple banking relationships simultaneously. Supports both LegitScript and non-LegitScript profiles. Ideal for practices recovering from shutdowns needing redundant processing.
Days to weeksDedicated ACH and eCheck programs with high approval rates for pharmaceutical merchants. Fees of 0.5 to 2 percent, no card brand restrictions, ideal for large recurring therapy orders.
Fast approvals| Processor Type | Typical Fees | Rolling Reserve | Approval Speed | LegitScript | Best For |
|---|---|---|---|---|---|
| Crypto-Bridge Settlement | 1 to 3% | 0% | Minutes | Not required | No freeze risk, instant settlement |
| US Domestic High-Risk Card | 3.5 to 5% | ~10% (3 to 6 mo) | Same day to 3 days | Not required | US RUO and MATCH-listed merchants |
| LegitScript-Aligned Acquirers | 2.95 to 4.5% | Custom | 24 to 72 hours | Required | GLP-1, semaglutide, 503A pharmacies |
| Offshore and International | 4 to 6%+ | ~10% | 1 to 2 days | Not required | High volume, global distribution |
| ACH and eCheck Specialists | 0.5 to 2% | Minimal | Fast | Optional | Recurring therapy billing, large orders |
| Traditional High-Risk | 5 to 8%+ | 10 to 15% | 1 to 6 weeks | Often required | Established certified pharmacy |
All fees and terms are determined solely by each processor after their own underwriting review. eData is a referral and matching service only.
eData Financial Group has been placing high-risk merchants with specialized banking relationships since 1997. Our pharmaceutical and medical payment concierge team works exclusively with physicians, compounding pharmacies, telehealth providers, and specialty clinics to ensure stable, compliant, and long-term processing solutions across the US, EU, and globally.
Request Concierge Matching →The global peptide therapeutics market exceeded $40 billion in 2024 and is projected to surpass $80 billion by 2030. Demand from physicians, pharmacies, and patients is accelerating worldwide. Here is what you need to know.
Peptides are short chains of amino acids — the building blocks of proteins — that act as biological messengers in the human body. They regulate virtually every physiological function: hormone production, immune response, tissue repair, metabolism, neurological signaling, and more. Because they are naturally occurring molecules, many have been studied extensively as the basis for pharmaceutical treatments.
The pharmaceutical industry has leveraged peptide science to develop some of the most impactful medications of the past century — from insulin for diabetes to GLP-1 agonists for obesity. Today, peptide-based drugs represent one of the most active areas of pharmaceutical research and clinical medicine globally.
Peptide drugs have the potential to revolutionize medicine, offering high specificity and low toxicity compared to small-molecule drugs. Over 239 peptide therapeutics have already received FDA approval across a wide range of indications.
GLP-1 receptor agonists such as semaglutide and tirzepatide represent a breakthrough in treating obesity and type 2 diabetes. Clinical trials show 15 to 22% body weight reduction — results previously only achievable through bariatric surgery. Demand for physician-supervised GLP-1 therapy is growing at over 40% annually in the US.
GoodRx — Peptides for Weight LossGrowth hormone-releasing peptides, GnRH analogues (leuprolide, gonadorelin), and tesamorelin are FDA-approved for conditions ranging from HIV-associated lipodystrophy to fertility protocols and hormone-related cancers. These are cornerstone medications in endocrinology and reproductive medicine worldwide.
NIH PMC — FDA-Approved Peptides in Medicine (2024)Parathyroid hormone analogues and related peptide drugs are FDA-approved for treating osteoporosis and significantly reducing fracture risk. As the global population ages, demand for bone-protecting peptide therapies is projected to grow substantially through 2035.
WebMD — What Are Peptides?Bioactive collagen peptides studied in peer-reviewed research demonstrate meaningful improvements in joint comfort, physical function, and body composition when combined with exercise. Studies show benefits at approximately 10 to 20g per day over 6 to 9 months for patients with joint pain and reduced mobility.
NIH PMC 2025 — Peptides in Nutrition and Musculoskeletal HealthPeptides targeting neurological signaling pathways are under active clinical investigation for cognitive decline, stroke recovery, and sleep disorders. Several peptide compounds have shown neuroprotective effects in peer-reviewed trials, making this one of the most promising frontiers in peptide medicine.
NIH PMC — Peptides for Health BenefitsThe THPdb database documents over 239 FDA-approved peptide and protein therapeutics, with oncology and immunology representing major categories. Peptide-based cancer treatments and immune modulators have transformed treatment outcomes across leukemia, lymphoma, prostate cancer, and autoimmune conditions.
PLOS One — THPdb: Database of 239+ FDA-Approved Peptide TherapeuticsThese are prescription medications legally used in clinical medicine. They are presented here strictly as educational examples of where peptide drugs are legitimately prescribed by licensed physicians. They are not products sold directly by eData.
| Therapeutic Area | Example Peptide Drugs | Key Indication | Reference |
|---|---|---|---|
| Diabetes and Obesity | Insulin analogs, Semaglutide, Tirzepatide, Liraglutide | Blood glucose control, chronic weight management with comorbidities | GoodRx |
| Endocrine and Hormone | Tesamorelin, Leuprolide, Gonadorelin, GH-releasing analogues | HIV lipodystrophy, fertility protocols, hormone-related cancers | NIH PMC |
| Bone Health | Parathyroid hormone analogues | Osteoporosis treatment, fracture risk reduction | WebMD |
| Oncology and Hematology | Multiple peptide therapeutics (see THPdb) | Cancer treatment, immune modulation, targeted therapy | PLOS One |
| Metabolic and Cardiovascular | Adiponectin receptor-targeting peptides (investigational and approved) | Metabolic syndrome, insulin sensitivity, cardiometabolic risk | NIH PMC |
| Total FDA-Approved Peptide and Protein Therapeutics | Over 239 approved therapeutics across oncology, hematology, autoimmune, endocrine, infectious disease, and more | THPdb / PLOS One | |
Peer-reviewed review of natural and engineered peptides approved by the FDA, including diabetes, growth hormone, and endocrine indications.
Read on NIH PMC →Complete database of approved peptide therapeutics with indication, route, and mechanism, hosted on PubMed Central.
Access THPdb →Reviews collagen peptide evidence for joint comfort, physical function, and body composition when combined with exercise.
Read Study →Consumer-level explanation of what peptides are, how they work in the body, and medically approved vs. experimental use.
Read on WebMD →Covers FDA-approved vs. non-approved peptides, RUO labeling, compounding restrictions, misbranding, and enforcement actions.
Read Legal Guide →Educational overview of peptide therapy including FDA bulk substances lists, compounding rules, and what to expect from licensed providers.
Read Guide →The information on this page is provided for general educational purposes only and is not medical advice. Peptide medications are regulated drugs that should only be used under the supervision of a licensed healthcare professional. Some peptides are FDA-approved prescription medications for specific indications; others remain investigational or are legally restricted to research use only and are not approved for human use in the United States. We do not manufacture, prescribe, or recommend any specific peptide products. Many peptides commonly marketed online for anti-aging, bodybuilding, or "research" have not been approved by the FDA for any use in humans — marketing these with medical claims may constitute misbranding under the Federal Food, Drug, and Cosmetic Act. Our platform requires merchants to comply with all applicable laws. Always consult a qualified healthcare professional before starting or stopping any medication or supplement.
eData Financial Group LLC provides payment processor referral services only. Approval to use our platform does not constitute an endorsement of any medical product or claim. We do not permit merchants to market non-approved peptides as treatments for diseases.
A pivotal regulatory window is open. Here is the timeline, what compounds are under review, and what it means for your practice and processing approval odds.
BPC-157, TB-500, KPV, Semax, Epitalon, MOTS-c and others removed from the FDA significant safety concerns list.
Submit scientific or clinical data to Docket FDA-2025-N-6895 to influence the committee's recommendations.
Committee evaluates 503A Bulks List inclusion for licensed compounding pharmacies operating under valid patient-specific prescriptions.
Reviewed for insomnia, opioid withdrawal, cerebral ischemia, trigeminal neuralgia, and sleep-related indications.
Five additional compounds reviewed for 503A Bulks List inclusion.
Positive PCAC outcomes would improve legitimacy, ease LegitScript certification, and unlock better processing terms with pharmacy-focused acquirers.
Strong disclaimers and no therapeutic claims remain essential regardless of outcomes. Compliant processing remains available today.
Processing approvals can be secured today. Waiting costs revenue. Favorable regulatory decisions will only improve what we can offer you.
The most common questions from medical professionals, pharmacists, and specialty clinic operators navigating pharmaceutical payment processing.
No bank statements required to begin. No commitment. Complete this form and a pharmaceutical payment specialist will review your profile personally and match you to the right processors within 24 hours.
The median time from first peptide transaction to processor termination is 2 to 6 weeks. Funds are frozen for up to 180 days. Applying before termination is always faster than recovering after.
By submitting you confirm your business is legitimate and compliant. eData Financial Group LLC is a referral and matching service only. We do not process payments directly. Approvals are determined solely by the processor after underwriting. We do not provide legal or regulatory advice. View our Privacy Policy and Terms and Conditions.
A pharmaceutical payment specialist will review your profile and present your processor matches within 24 hours.
Ensure your website displays "For Research Use Only, Not for Human Consumption" disclaimers where applicable to maximize approval odds.
Questions? +1-561-395-9554